ArticleBMC musculoskeletal disorders2026
Glucagon-like peptide-1 receptor agonists and rotator cuff disease: a scoping review.
Article in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity and type 2 diabetes mellitus (T2DM) are associated with impaired rotator cuff tendon healing and inferior clinical outcomes following surgical repair. Glucagon-like peptide-1 receptor agonists (GLP-1RA) are increasingly used to manage obesity and T2DM. However, their influence on rotator cuff disease biology and outcomes following cuff repair remains unknown.
methodsA scoping review was conducted in accordance with PRISMA-ScR guidelines. MEDLINE, Embase, PubMed, and the Cochrane Library were searched from inception to 28 January 2026 for studies evaluating associations between GLP-1RA exposure and rotator cuff disease. Eligible studies included human observational cohort studies and preclinical experimental studies. Data were extracted independently by two reviewers and synthesised descriptively.
resultsSix studies were included, four human retrospective cohort studies and two controlled preclinical studies. The human studies included 1,481,529 patients, of which 391,716 were GLP-1RA users. Preoperative GLP-1RA use was not associated with increased postoperative complications following rotator cuff repair. However, GLP-1RA use was associated with increased incidence of atraumatic rotator cuff tears and subsequent repair. Preclinical models of acute rotator cuff injury and repair found that liraglutide improved biomechanical strength and organisation of the repaired tendon-bone interface, reduced fatty infiltration, and attenuated cellular stress responses.
conclusionsThe current evidence does not demonstrate an association between GLP-1RA use and increased risk of postoperative complications following rotator cuff repair. Studies reported an association between GLP-1RA use and higher incidence of atraumatic rotator cuff tears. Preclinical data suggest GLP-1RA may influence rotator cuff tissue healing. High-quality prospective studies are required to clarify the effects of GLP-1RA on rotator cuff disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.